How many years can you live with ibrutinib/ibrutinib treatment?

Ibrutinib/Ibrutinib is a new type of targeted therapy drug that is widely used in the treatment of hematological malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom's macroglobulinemia (WM), graft versus host disease (cGVHD) and other hematological malignancies. Factors such as different patients' conditions, individual differences, and treatment options will directly affect the patient's survival period.

Based on research data and clinical practice, ibrutinib has shown therapeutic efficacy in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. One study found that progression-free survival was prolonged in patients with chronic lymphocytic leukemia treated with ibrutinib. The average duration of treatment in clinical trials was approximately 41 months (range, 2-51 months). Among patients who discontinued ibrutinib, the average survival after discontinuation was 8 months.

Ibrutinib is generally continued indefinitely with good tolerability, limited disease progression, and no toxicity. Some people may have very good partial clinical responses in three to six months. However, most patients remain on ibrutinib indefinitely, regardless of clinical response. This is a common treatment strategy for patients with certain types of leukemia and solid tumors because often when the therapeutic agent is stopped, symptoms return within a relatively short period of time and the lymph nodes enlarge, especially if the patient has not been taking ibrutinib for a long time or if they have tried many other treatments before.

During the patient's treatment with ibrutinib, the doctor will monitor the efficacy and side effects based on the patient's condition, and make treatment adjustments as needed. It is important that patients cooperate closely with their doctor's guidance and management, follow the treatment plan, and have regular follow-up visits.